argenx SE (VIE:ARGX)
Austria
· Delayed Price · Currency is EUR | Market Cap | 38.31B |
| Revenue (ttm) | 3.62B |
| Net Income (ttm) | 1.10B |
| Shares Out | n/a |
| EPS (ttm) | 16.67 |
| PE Ratio | 34.81 |
| Forward PE | 26.02 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 4 |
| Open | 643.60 |
| Previous Close | 649.60 |
| Day's Range | 641.80 - 648.60 |
| 52-Week Range | 457.20 - 805.00 |
| Beta | n/a |
| RSI | 33.43 |
| Earnings Date | Feb 26, 2026 |
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ... [Read more]
Financial Performance
In 2025, argenx SE's revenue was $4.25 billion, an increase of 88.95% compared to the previous year's $2.25 billion. Earnings were $1.29 billion, an increase of 55.10%.
Financial numbers in USD Financial StatementsNews
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
Positive results from Phase 3 ADAPT OCULUS study show VYVGART's potential as the first targeted treatment for patients living with ocular MG Additional data from ADAPT SERON – the largest study of pat...
Oversold Conditions For argenx (ARGX)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
argenx SE 2025 Q4 - Results - Earnings Call Presentation
Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today
argenx (NASDAQ: ARGX) has outperformed the market over the past 5 years by 6.83% on an annualized basis producing an average annual return of 18.92%. Currently, argenx has a market capitalization of ...
Baron Health Care Fund Q4 2025 Contributors And Detractors
Eli Lilly and Company's shares rose during the quarter as Zepbound's obesity launch continued to gain strong traction. Cidara Therapeutics' shares rose further following Merck's acquisition of the com...
argenx SE at TD Cowen Healthcare Conference Transcript
argenx SE at TD Cowen Healthcare Conference Transcript
RBC Capital Lowers Price Target for argenx (ARGX) Amidst Maintained 'Outperform' Rating | ARGX ...
RBC Capital Lowers Price Target for argenx (ARGX) Amidst Maintained 'Outperform' Rating | ARGX Stock News
Wells Fargo Lowers Price Target for argenx (ARGX) but Maintains Overweight Rating | ARGX Stock News
Wells Fargo Lowers Price Target for argenx (ARGX) but Maintains Overweight Rating | ARGX Stock News
ARGX Stock Rating Update: Citizens Raises Price Target to $944 | ARGX Stock News
ARGX Stock Rating Update: Citizens Raises Price Target to $944 | ARGX Stock News
These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
Argenx SE (NASDAQ: ARGX) on Thursday reported upbeat fourth-quarter results and announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART in adults with ocular myasthe...
These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
Argenx SE (NASDAQ: ARGX) on Thursday reported upbeat fourth-quarter results and announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART in adults with ocular myasthen...
ARGX: Guggenheim Lowers Price Target While Maintaining 'Buy' Rating | ARGX Stock News
ARGX: Guggenheim Lowers Price Target While Maintaining 'Buy' Rating | ARGX Stock News
ARGX: Baird Maintains 'Neutral' Rating, Price Target Raised to $867 | ARGX Stock News
ARGX: Baird Maintains 'Neutral' Rating, Price Target Raised to $867 | ARGX Stock News
Baron International Growth Fund Q4 2025: Contributors, Detractors, And Trades
For 2025, we underperformed the Benchmark, while to a lesser extent also trailing our all-cap international growth Proxy Benchmark. The underperformance was in our view attributable to an abrupt but m...
argenx SE (ARGNF) Q4 2025 Earnings Call Highlights: Record Growth and Strategic Advances
argenx SE (ARGNF) Q4 2025 Earnings Call Highlights: Record Growth and Strategic Advances
Q4 2025 argenx SE Earnings Call Transcript
Q4 2025 argenx SE Earnings Call Transcript
argenx SE (ARGX) Q4 2025 Earnings Call Transcript
argenx SE (ARGX) Q4 2025 Earnings Call Transcript
Argenx Touts Positive Phase 3 Eye Disease Study Results
Argenx SE (NASDAQ: ARGX) on Thursday announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART in adults with ocular myasthenia gravis (oMG).
Argenx Touts Positive Phase 3 Eye Disease Study Results
Argenx SE (NASDAQ: ARGX) on Thursday announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART in adults with ocular myasthenia gravis (oMG). It is an autoimmune disor...
Argenx Posts Strong 2025 Results And Reports Positive Phase 3 Results In Ocular MG
(RTTNews) - Argenx SE (ARGX) has reported encouraging fourth-quarter and full-year 2025 results, marked by significant growth in global product net sales and continued expansion of the VYVGART franchi...
Artisan Global Discovery Fund Q4 2025 Winners, Laggards, Buys & Sells
The portfolio generated strong absolute returns in Q4 and 2025 but trailed the MSCI All Country World Small Mid Index over each period. Stock selection in health care was the strongest contributor to ...
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE: ENOV) is estimated to report quarterly earnings at $0.83 per share on revenue of $583.03 million. • Fortrea Holdings (NASDAQ: FTRE) is estimated t...
Argenx (ARGX) Surpasses Revenue Expectations with Strong 2025 Performance
Argenx (ARGX) Surpasses Revenue Expectations with Strong 2025 Performance
argenx SE (ARGX) Reports Q4 Earnings Beat Amid Revenue Miss
argenx SE (ARGX) Reports Q4 Earnings Beat Amid Revenue Miss